Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
187 studies found for:    "Immune thrombocytopenia"
Show Display Options
Rank Status Study
1 Not yet recruiting A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Intervention: Drug: Bortezomib
2 Recruiting A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention: Drug: Decitabine
3 Withdrawn The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention:
4 Recruiting Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Romiplostin
5 Withdrawn A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Interventions: Drug: Cyclosporin A;   Drug: rhTPO
6 Completed An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Intervention: Drug: Dexamethasone
7 Active, not recruiting Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Intervention: Other: blood sample
8 Completed An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention: Drug: Human immunoglobulin intravenous
9 Unknown  Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Antox tablets(Mepaco);   Other: drug therapy for ITP
10 Recruiting Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention: Drug: PRTX-100
11 Recruiting Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Rituximab;   Drug: Eltrombopag;   Drug: Dexamethasone
12 Recruiting Open-Label, Dose Escalation Study of PRTX-100 in Adults With Persistent/Chronic Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention: Drug: PRTX-100
13 Withdrawn Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Interventions: Drug: Dexamethasone (4 cycles);   Drug: Dexamethasone (1 cycle)
14 Not yet recruiting Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Rituximab;   Drug: Dexamethasone;   Drug: Mycophenolate mofetil;   Drug: Placebo
15 Recruiting Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Interventions: Drug: Romiplostim;   Drug: Placebo
16 Active, not recruiting This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Intervention: Biological: BT595
17 Recruiting Immune Thrombocytopenia in Pregnancy
Conditions: Immune Thrombocytopenia;   Pregnancy
Intervention: Other: No intervention
18 Completed Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)
Condition: Immune Thrombocytopenia Purpura
Interventions: Drug: MK-8723;   Drug: Matching Placebo
19 Terminated A Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered to Adult Subjects With Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia (ITP)
Interventions: Drug: placebo to S-888711;   Drug: S-888711
20 Completed Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia
Condition: Primary Immune Thrombocytopenia
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.